Balancing immunity and immunosuppression: Vaccinating patients receiving treatment with efalizumab

Journal of Investigative Dermatology

Volumn 128, Issue 11, 2008, Pages 2567-2569

  Marmon, Shana ^a   Strober, Bruce E ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

DRUG PROTEIN BINDING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; NOTE; PRIORITY JOURNAL; PSORIASIS; VACCINATION;

EID: 53949123379     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.291     Document Type: Note

References (11)

1. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243-52
2. Anderson ME, Siahaan TJ (2003) Targeting ICAM-1/ LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24:487-501
3. Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD et al. (2005) Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 5:50-7
4. Cavazzana-Calvo M, Sarnacki S, Haddad E, De Coene C, Calise D, Yvon E et al. (1995) Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Transplantation 59:1576-82
5. Dengler TJ, Strnad N, Buhring I, Zimmermann R, Girgsdies O, Kubler WE et al. (1998) Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 66:1340-7
6. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD et al. (2003) CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 49:816-25
7. Kipnis CD, Myers WA, Opeola M, Gottlieb AB (2005) Biologic treatments for psoriasis. J Am Acad Dermatol 52:671-82
8. Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W (2008) Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single-blind study. J Invest Dermatol 128:2615-24
9. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X et al. (2005) Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 27:1317-28
10. Strober BE, Clarke S (2004) Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol 3:270-2
11. Vinuesa CG, de Lucas C, Cook MC (2001) Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens. Postgrad Med J 77:562-9